AIC
GCVRZ

Ameritas Investment Company’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Ameritas Investment Company’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-165
Closed – – 2134
2018
Q4 		$0 Buy
+165
New +$82 ﹤0.01% 1631

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Ameritas Investment Company's GCVRZ Position: Q1 2019 in Review

Ameritas Investment Company sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2019, closing a stake of 165 shares.

Ameritas Investment Company first reported a position in GCVRZ in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 105 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2019.

  • Ameritas Investment Company reported no remaining Sanofi Contingent Value Rights position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 165 Sanofi Contingent Value Rights shares in Q1 2019.
  • Ameritas Investment Company first reported a position in Sanofi Contingent Value Rights in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Sanofi Contingent Value Rights position peaked at $0 in Q4 2018.
  • 105 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.